The Management of Lung Cancer: A UK Survey of Oncologists

Clinical Oncology

Volumn 24, Issue 6, 2012, Pages 402-409

  Prewett, S L ^a   Aslam, S ^a   Williams, M V ^a   Gilligan, D ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Lung cancer; NCRN trials; NICE; Radiotherapy; SBRT

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; NAVELBINE; PEMETREXED;

ADVISORY COMMITTEE; ARTICLE; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEALTH CARE SURVEY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; SKULL IRRADIATION; STEREOTACTIC BODY RADIATION THERAPY; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; GREAT BRITAIN; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 84863843965     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.03.005     Document Type: Article

References (34)

1. Ash D., Barrett A., Hinks A., Squire C. Re-audit of radiotherapy waiting times 2003. Clin Oncol 2004, 16:387-394.
2. Department of Health. Cancer waiting times. Available at: . [last accessed 24.06.11]. http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/Performancedataandstatistics/HospitalWaitingTimesandListStatistics/CancerWaitingTimes/index.htm.
3. Barton M.B., Frommer M., Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006, 7(7):584-595.
4. Williams M.V., Drinkwater K.J. Radiotherapy in England in 2007: modelled demand and audited activity. Clin Oncol 2009, 21(8):575-590.
5. NRAG report 2007. Available at: . http://www.cancer.nhs.uk/radiotherapy/nrag.htm.
6. Coleman M.P., Forman D., Bryant H., et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-138.
7. Williams M.V., Drinkwater K.J. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation. Clin Oncol 2009, 21(6):431-440.
8. Rich A.L., Tata L.J., Stanley R.A., et al. Lung cancer in England: information from the National Lung Cancer Audit (LUCADA). Lung Cancer 2011, 72:16-22.
9. NICE clinical guideline CG121 on lung cancer. Available at: . http://www.nice.org.uk/nicemedia/live/13465/54199/54199.pdf.
10. NICE clinical guideline CG24 on lung cancer. Available at: . http://www.nice.org.uk/nicemedia/live/10962/29675/29675.pdf.
11. Radiotherapy dose-fractionation 2006, Royal College of Radiologists, BFCO(06)1, Royal College of Radiologists, London. http://www.rcr.ac.uk/publications.aspx?3fPageID=3d149&26PublicationID=3d229.
12. http://public.ukcrn.org.uk/Search/StudyDetail.aspx?3fStudyID=3d9471.
13. Saunders M.I., Rojas A., Lyn B.E., et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998, 78:1323-1328.
14. Hatton M.Q.F., Martin J.E. Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions. Clin Oncol 2010, 22:356-364.
15. ASCO proceedings 2011 [abstract 7039]. Available at:. http://abstract.asco.org/AbstView_102_80891.html.
16. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High dose radiation improved local tumour control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:324-333.
17. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: a phase 1-2 dose escalation study using 3-dimensional conformal radiotherapy in patients with inoperable non small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(2):318-328.
18. Rosenzweig K.E., Fox J.L., Yorke E., et al. Results of a phase 1 escalation study using 3-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung carcinoma. Cancer 2005, 103:2118-2127.
19. National Radiotherapy Implementation Group Report. Stereotactic body radiotherapy. Available at: . http://ncat.nhs.uk/sites/default/files/NRIG%20SBRT%20Final%20June%2011.pdf.
20. National Radiotherapy Implementation Group Report. Clinical review of the evidence for SBRT. Available at:. http://ncat.nhs.uk/sites/default/files/clinical%20evidence%20review%20Dec%2010%20-%20Final%20J11.pdf.
21. Rowell N.P., O'Rourke N.P. Concurrent chemo-radiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004, 4.
22. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995, 311:899-909. NSCLC Collaborative Group.
23. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46(1):87-98.
24. O'Rourke N., Macbeth F. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol 2010, 22(5):347-355.
25. Auperin A., Le Pechoux C., Rolland E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190.
26. Fried D.B., Morris D.E., Poole C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004, 22(23):4837-4845.
27. Turrissi A., Kyungmann K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited stage small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
28. Auperin A., Arriiagada R., Pignon J.-P., et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Eng J Med 1999, 341:476-484.
29. Le Pechoux C., Dunanat A., Senan S., et al. Standard-dose versus higher dose prophylactic cranial irradiation (PCI) in patients with limited stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009, 10:467-474.
30. Le Pechoux C., Laplanche A., Faivre-Finn C., et al. Clinical neurological outcome and quality of life among patients with limited small cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0210 and IFCT 99-01). Ann Oncol 2011, 22(5):1154-1163.
31. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive stage small-cell lung cancer. N Engl J Med 2007, 357:664-672.
32. Martin A., Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol 2010, 22(3):157-172.
33. Yap M.L., Vinod S.K., Shon I.A., et al. The registration of diagnostic versus planning FDG PET/CT in radiotherapy planning for NSCLC. Clin Oncol 2010.
34. Hatton M, Nankivell M, Lyn E, et al. Induction chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for patients with locally advanced inoperable non-small cell lung cancer: the MRC INCH randomised trial. 13th world conference on lung cancer B5.5.